Biocon Limited concluded FY26 with a resilient performance, marking a significant transition into a unified biopharma entity. The company reported a 10% year-on-year revenue growth in the fourth quarter, driven by strong biosimilars demand. With the major investment phase now substantially complete, Biocon is shifting its focus toward disciplined execution, operating leverage, and sustained deleveraging to strengthen its balance sheet and improve returns for shareholders in the upcoming financial year.
Financial Highlights of Q4 FY26
Biocon delivered a strong finish to the 2026 fiscal year, reporting a 10% year-on-year growth in operating revenue for the fourth quarter. The group’s EBITDA stood at ₹1,073 crores, representing a robust margin of 23%. Adjusted for the one-time lenalidomide benefit in the prior-year base, this marks a significant 29% growth in EBITDA, underscoring the efficiency of the company’s integrated operating model.
Segment-Wise Performance
The Biosimilars segment emerged as a primary growth driver, achieving 12% year-on-year growth with a revenue of ₹2,756 crores and a strong EBITDA margin of 26%. The Generics business also demonstrated resilience, growing 13% year-on-year (excluding lenalidomide), while the CRDMO division contributed ₹1,037 crores to the quarterly revenue, reflecting a 2% year-on-year increase.
Strategic Milestones and Future Outlook
Having concluded the seamless integration of its biosimilars and generics businesses in under 100 days, Biocon has entered a phase focused on value creation. Management highlighted that the heavy lifting regarding capital expenditure is largely behind them. The company’s focus for FY27 is to capitalize on newly launched products, such as Yesintek, Bosaya, and Aukelso, and to leverage its strengthened balance sheet to reduce debt. With the Malaysia plant expansion and debottlenecking efforts in Bangalore, Biocon is well-positioned to scale its operations to meet rising global demand.
Driving Sustainable Growth
Looking ahead, Biocon aims to drive long-term value by prioritizing profitable growth over immediate market share expansion. The company expects performance to improve progressively throughout FY27, particularly as recent pipeline approvals—including liraglutide and various denosumab biosimilars—translate into commercial scale. The emphasis remains on disciplined execution and maximizing the return on capital employed as the organization moves into its next phase of growth.
Source: BSE
